The Binding of Religious Heroes in Andreas and the Hêliand

Scholarly approaches to the Old English Andreas have tended to emphasise the poem's formulaic debt to Beowulf and the works of Cynewulf, but as of yet unexplored is its strikingly similar use of the binding motif also present in the Old Saxon alliterative gospel, the Hêliand. These two poems, likely produced in a similar period, share not only a depiction of bound religious heroes that far outstrips their sources, but also specific formulaic and linguistic parallels. The suggestion that the Hêliand's preoccupation with the binding of Christ stems directly from the experience of those Saxons subjugated by the Franks is, therefore, problematised when we take into account the formulaic nature of binding terminology in the closely related language of Old English. Similarly, a desire to read the binding of the saints in Andreas as a unique innovation does not take into account the possibility that the poet may have been familiar with a tradition in which Christ's Passion includes binding. In discussing these two texts together, this paper emphasises a cross-cultural interest in bondage, as well as the importance of exploring formulaic connections between the Old English and Old Saxon corpora

Targeted prodrug design to optimize drug delivery

Classical prodrug design often represents a nonspecific chemical approach to mask undesirable drug properties such as limited bioavailability, lack of site specificity, and chemical instability. On the other hand, targeted prodrug design represents a new strategy for directed and efficient drug delivery. Particularly, targeting the prodrugs to a specific enzyme or a specific membrane transporter, or both, has potential as a selective drug delivery system in cancer chemotherapy or as an efficient oral drug delivery system. Site-selective targeting with prodrugs can be further enhanced by the simultaneous use of gene delivery to express the requisite enzymes or transporters. This review highlights evolving strategies in targeted prodrug design, including antibody-directed enzyme prodrug therapy, genedirected enzyme prodrug therapy, and peptide transporter-associated prodrug therapy